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Potential targetAbstract G protein coupled receptors (GPCRs) represent the most important targets in modern
pharmacology because of the different functions they mediate, especially within brain and periph-
eral nervous system, and also because of their functional and stereochemical properties. In this
paper, we illustrate, via a variety of examples, novel advances about the GPCR-related molecules
that have been shown to play diverse roles in GPCR pathways and in pathophysiological phenom-
ena. We have exempliﬁed how those GPCRs’ pathways are, or might constitute, potential targets
for different drugs either to stimulate, modify, regulate or inhibit the cellular mechanisms that
are hypothesized to govern some pathologic, physiologic, biologic and cellular or molecular aspects
both in vivo and in vitro. Therefore, inﬂuencing such pathways will, undoubtedly, lead to different
therapeutical applications based on the related pharmacological implications. Furthermore, such
new properties can be applied in different ﬁelds. In addition to offering fruitful directions for future
researches, we hope the reviewed data, together with the elements found within the cited references,
will inspire clinicians and researchers devoted to the studies on GPCR’s properties.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.Contents
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Among cell surface receptors, Heptahelical GPCRs constitute
the largest single family (Lagerstrom and Schioth, 2008).
Whereas, this family is estimated to comprise at least 800 mem-
bers in the human genome (Gloriam et al., 2007), it constitutes
the largest protein family in vertebrates (Schulein et al., 2012).
This family was recognized in 1986 after a work that has
shown a sequence similarity between rhodopsin and the
b2AR (Dixon et al., 1986). In addition to cell surface, GPCRs
are suggested to exist in the endoplasmic reticulum, Golgi
apparatus, nuclear membrane and even inside the nucleus itself
(Boivin et al., 2008; Calebiro et al., 2010; Cheng et al., 2011;
Re et al., 2010). Diverse array of endogenous ligands (stimuli)
activate GPCRs including biogenic amines, neuropeptides,
amino acids, ions, hormones, chemokines, lipid-derived medi-
ators, proteases peptides, proteins, photons (Hazell et al.,
2012; Marinissen and Gutkind, 2001), protons (H+) and ions
(Ca2+) (Lagerstrom and Schioth, 2008). In contrast, we have
orphan GPCRs with non identiﬁed endogenous ligand (Chung
et al., 2008). It is estimated that between 120 and 130 receptors
are non-chemosensory orphan GPCRs (Gloriam et al., 2007;
Harmar et al., 2009). Genetic statistics showed that olfactory
receptors constitute about 50% of all GPCRs in the human
genome (Gloriam et al., 2007) and at least 22 genes code for
the class C of GPCRs in humans (Rondard et al., 2011).
The combination of novel advances and innovative re-
search methods such as recent cloning of some mammalian
GPCRs (Heberlein et al., 2009) and comparative studies of
gene expression proﬁles of human postmortem brains coming
from both patients with neurological disorders and healthy
individuals(Horvath et al., 2011; Iwamoto and Kato, 2006;
Mehta et al., 2010; Sequeira and Turecki, 2006), with the appli-
cations of biochemical, mutagenesis and spectroscopic tech-
niques (Gether, 2000), help to further the understanding of
GPCRs’ properties and provide more data to develop new
therapeutic strategies via targeting GPCRs.2. GPCRs: from physiology to pharmacology
The pharmacological properties, we emphasize herein, lie basi-
cally on different functions of either GPCRs or the molecules
involved in the GPCR-related mechanisms. Different receptors
illustrate this concept. Indeed, whereas, glutamatergic and
GABAergic neurotransmitters within amygdala have been
linked with emotions, fear regulations, anxiety, learning and
memory processes (LeDoux, 2000; Roozendaal et al., 2009),
serotonin (5-HT) which is found throughout the central and
the peripheral nervous system (Parkel et al., 2011) plays a reg-
ulatory role in the cerebral anxiety behaviors (Li et al., 2012)thermoregulation (Balcells-Olivero et al., 1998) (Seletti et al.,
1995) , sexual behavior (Maswood et al., 1998), memory
(Edagawa et al., 1998) immune function(Iken et al., 1995;
Rauly-Lestienne et al., 2011), sleep, appetite and pain percep-
tion processes (Werry et al., 2008). Furthermore, 5-HT1A
receptor has been linked with depression (Blier et al., 1997;
Savitz et al., 2009) memory and cognitive function (Bert
et al., 2008). GPCRs have also even been shown to play a role
in sweet taste perception (Adler et al., 2000; Assadi-Porter
et al., 2010; Hoon et al., 1999; Koizumi et al., 2007). Impor-
tantly, the key molecules of the neural network, which are
the metabotropic glutamate receptors (mGlu), are GPCRs
(Nicoletti et al., 2011) as well. Consequently different GPCRs
and GPCR pathway-related molecules are already or may turn
out to be targets for different drugs. As illustration, aminergic
receptors (Insel et al., 2007) and serotonin1A receptor consti-
tute the target for neuropsychiatric disorder treatment (Gan-
guly et al., 2011).
GPCRs, which are metabotropic receptors(Serebryany
et al., 2012), constitute the most important class of pharmaco-
logical targets in all clinical areas (Lagerstrom and Schioth,
2008) and different estimations about the portion of drugs
interacting with GPCRs exist. Indeed, several papers have
indicated that this portion is between 30% and 60% (Hopkins
and Groom, 2002; Lundstrom, 2006), whereas authors have
estimated that nearly half of the pharmakons interact directly
or indirectly with these 7 transmembrane receptors (7TMRs)
(Heilker et al., 2009; Lagerstrom and Schioth, 2008).
In addition, to controlling a large number of physiological
processes, such as signal transduction (Davies et al., 2007; Lag-
erstrom and Schioth, 2008) ligand diversity and unique tissue
expression(Ma and Zemmel, 2002), GPCRs exist in a high
number and have the property of ‘‘ligand binding speciﬁcity’’
(Lagerstrom and Schioth, 2008). More importantly, among
all hormones and neurotransmitters we estimate that 80% of
them exert their effects via interacting with GPCRs
(Birnbaumer et al., 1990). All these properties increase the
pharmacological importance of GPCRs and make such
receptors ideal therapeutic targets for different diseases.
GPCR ligands can be classiﬁed into antagonists and agonists
(which include full agonists and partial agonists) in addition
to a relatively new class, inverse agonists (Ambrosio et al.,
2011). Many pharmaceutical companies are working on the
identiﬁcation of agents that target GPCRs (Lagerstrom and
Schioth, 2008; Overington et al., 2006) and advances about
factors such as those inﬂuencing GPCRs’ activity (Ghanemi
et al., 2013) can be further investigated in drug development.
Until now we know many drugs with an activity based on
the interaction with GPCR-related system including block-
busters such as opiates, antihistamines, a- and b-blockers, b-
agonists, dopamine receptor blockers, angiotensin receptor
Targeting G protein coupled receptor-related pathways as emerging molecular therapies 117blockers, angiotensin – converting enzyme inhibitors and selec-
tive serotonin reuptake inhibitors (Whalen et al., 2011). Fur-
thermore, sweet-taste synergisms, mediated by GPCRs, have
been linked with some molecules used as sweeteners like Neo-
hesperidin dihydrochalcone (NHDC) and cyclamate that syn-
ergistically potentiated cell response to sucrose (Birch, 1999;
Schiffman et al., 1995) Such ﬁndings could allow us to reduce
sugar contents in some beverage and food and thus, provide a
new form of healthy diet products or a starting point to devel-
op novel substitute for diabetics and other kind of metabolic
diseases-related diet. This illustrates a non-therapeutical appli-
cation of GPCRs’ advances as well.
3. Signal transduction and pathways
The main common mechanism of GPCRs’ function is to re-
ceive an external signal (bind to ligands which constitute the
ﬁrst messenger) and convert that stimulus into a cellular re-
sponse within the intracellular medium via a chain of biochem-
ical reactions and molecular interactions. After GPCR
activation by the ligand(s) the receptor rearranges, which in-
duces signal transduction to the cytoplasmic side (Serebryany
et al., 2012). According to the existence or the non existence
of bound ligands to it, GPCRs have two states, high and low
afﬁnity states, which correspond to G protein-coupled and
uncoupled states (Ma et al., 2011). The physical description
of ligand-receptor interactions involves intermolecular forces
including ionic bonds, hydrogen bonds and van der Waals
forces that, all together, induce a spatial conformational
change in the tertiary structure of the GPCR (Ma et al.,
2002). Then it activates downstream signaling cascades within
the cell (Park et al., 2008; Pierce et al., 2002; Rosenbaum et al.,
2009).
GPCRs are suggested to have similar topology and activa-
tion mechanisms (Hofmann et al., 2009; Rosenbaum et al.,
2009) but with different G proteins’ subtypes involved within
the diverse signal-transduction pathways (Rosenbaum et al.,
2009). In fact, G protein has three subunits: Ga, Gb and Gc
(Hazell et al., 2012) with at least 16 Ga, 5 Gb, and 12 Gc sub-
units in the human genome (Robishaw and Berlot, 2004). To
achieve their cellular functions, GPCRs interact with multiple
associated proteins which constitute intracellular networks
(Hazell et al., 2012). These networks involve a variety of pro-
tein molecules such as GPCR kinase (GRK), which can phos-
phorylate and regulate nuclear proteins including class II
histone deacetylases (HDACs) (Martini et al., 2008), and arr-
estin (Krupnick et al., 1997; Wilden, 1995). These network-re-
lated protein molecules govern different mechanisms and
biochemical reactions that lead, according to the receptor
and the cell types, to the intracellular increase in protein kinase
C (PKC), protein kinase A (PKA) activity, intracellular cal-
cium (Ca2+), cyclic AMP (Camps et al., 1992; Hazell et al.,
2012) and a phosphorylation activity too (Wilden, 1995),
which is very important within the downstream activity of
some GPCRs. Furthermore, it is suggested that GPCR signal-
ing can affect the dynamic reorganization of the actin cytoskel-
eton (Ganguly et al., 2011). GPCRs’ activation implicates,
depending on the receptor type or subtype, the activation of
intracellular signals that are mediated by an arsenal of biomol-
ecules including Gbc, guanosine diphosphate (GDP), adenylyl
cyclases (AC), phosphodiesterases, phospholipases, tyrosinekinases and ion channels (Cabrera-Vera et al., 2003) resulting
in the regulation of numerous biological functions (Cabrera-
Vera et al., 2003). Although GPCRs have a similar mechanism
of activation, the molecules involved in signal transduction
may not be the same .For example, serotonin 5-HT4 receptors
involve Gs, Src, cAMP and MAP kinase (Barthet et al., 2007),
whereas b2-adrenoceptors(b2-AR) involve both Gs-coupled
and G a-independent/tyrosine kinase Src-dependent pathway
(Sun et al., 2007).
GPCRs have a functional selectivity and can activate,
depending on the ligand nature, more than one class of G pro-
teins (Kenakin andMiller, 2010;Maudsley et al., 2005;Woehler
and Ponimaskin, 2009; Zheng et al., 2010) making this area of
pharmacodynamics more interesting. Moreover, due to the efﬁ-
cacies’ differences, distinct ligands may generate different active
states of GPCRs (Ambrosio et al., 2011) resulting in a pharma-
cological diversity. More importantly, protein G-independent
interactions have been shown for GPCRs as well, mainly with
b-arrestins (Beaulieu et al., 2005; Lefkowitz and Shenoy, 2005;
Luttrell et al., 1999). Although G protein dependant regulation
remains the principalmechanism inGPCRs’ activation, b-arres-
tin dependant regulation is an emerging pathway (Whalen et al.,
2011). The bArrestin binding to a receptor initiates the internal-
ization of that receptor (Daaka, 2011). Importantly, some
GPCRs are able to activate both G protein-dependent and G
protein-independent pathways (Feng et al., 2005).
GPCRs’ signals transductions can lead to a variety of cellu-
lar responses including growth, death, movement, transcrip-
tion and excitation (Gloriam et al., 2007; Marinissen and
Gutkind, 2001). Importantly, the existent signal ampliﬁcation
and modulation within the pathway through downstream sig-
naling cascades (Serebryany et al., 2012) makes this pathway
more important in both cell physiology and pharmacology.
4. Modifying GPCR-related pathways: not less important that
targeting GPCRs
By ‘‘GPCR-related system’’ we refer, herein, to GPCRs, their
endogenous ligands and both the enzymes and molecules with-
in both the cells and the synaptic gaps, that are related to the
activation, the regulation or the inactivation of GPCR related
pathways. This novel area is fueled by new discoveries and tar-
geting GPCR-related pathways, by diverse compounds, consti-
tutes one of the most important approaches among the
emerging therapies. Thus, the diverse novel molecules target-
ing GPCR systems, that might provide new therapeutics, re-
main the most interesting topic of the researches on GPCRs
which focus on their high pharmacological importance.
GPCR pathways involve multiple cell signaling cascades
and networks within the cells some of which are beneﬁcial or
compensatory and others deleterious. The balance between
these pathways, which in a large part is dictated by the cellular
environment, determines the outcome as a diseased or non-dis-
eased state. Therefore, understanding the signaling mecha-
nisms activated by, basically, various neurohormonal stimuli
has led to novel ideas about potential agents that target those
cell signaling cascades. Within this paper we focus on the
importance of targeting or modifying molecules that are impli-
cated in both signal transduction and pathway downstream
signaling of GPCRs rather than the concept of directly target-
ing receptor by agonists or antagonists.
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receptor therapies is underappreciated, for that matter we
put more light on how understanding, than modifying signal-
transduction pathways of the GPCR-related mechanisms, by
different methodologies including genetic approaches or differ-
ent natural or chemical compounds, can provide potential
therapies and novel starting points to develop active agents
against a diversity of diseases and disorders.4.1. b-Arrestins
Since GPCRs’, or seven transmembrane receptors’ (7TMR),
functions have been shown to involve b-arrestins in a diversity
of physiological and pathogenesis phenomena, inﬂuencing the
b-arrestin pathway might provide novel therapies. Functions
such as the activities of bronchial b2Adrenoreceptors’
(b2AR) desensitization (Deshpande et al., 2008; Wang et al.,
2009) D1 dopamine-receptor – related striatal neuron apopto-
sis (Chen et al., 2009), angiotensin II type 1A receptor (AT1R)
mediated protein-cell synthesis and antiapoptosis in vascular
smooth-muscle (Ahn et al., 2009; DeWire et al., 2008) are
linked to b-arrestins. Furthermore, b-arrestins are implicated
in a number of toxicological processes including alcohol expo-
sure, consumption and reward (Bjork et al., 2008; Rimondini
et al., 2002) and limiting opioid-induced reward (Bohn et al.,
2003). Moreover, b-arrestins have been shown to play roles
not only in many physiological aspects but also in the patho-
genesis of some diseases (Luttrell and Gesty-Palmer, 2010;
Schmid and Bohn, 2009). The b-Arrestin-related pathways in-
volve a variety of mechanisms (Christensen et al., 2010;
DeWire et al., 2007; Xiao et al., 2007; Xiao et al., 2010) includ-
ing even functions that are independent from those modulating
GPCR pathways (Kim et al., 2008). Molecular pharmacology
has shown that b-arrestin2 desensitizes GPCR via two mecha-
nisms, (1) recruiting phosphodiesterases to degrade the cAMP
generated by G protein signaling (Perry et al., 2002) and (2)
internalizing receptor (Ahn et al., 2003), both mechanisms will
result in the sterical prevention of the interaction between theFigure 1 Signaling of biased ligands which have the ability to stimul
the selectivity they have at the receptor level and the therapeutic imp
either b-arrestin activation or G protein activation).GPCR and its G protein (Lohse et al., 1990). More impor-
tantly, evidence about b-arrestin is pointing out the concept
of ‘‘biased agonism’’ (Kenakin, 2005; Kenakin and Miller,
2010; Rajagopal et al., 2010; Violin and Lefkowitz, 2007), a
concept reviewed recently by Whalen et al. (2011). ‘‘Biased
agonism’’ is described as the ability of a ligand, which after
binding to a GPCR, promotes either the pathway involving
only G protein signaling or only b-arrestin mediated signaling
(Fig. 1). Two other publications have described the same con-
cept of ‘‘biased agonism’’ as a ‘‘functional selectivity’’ (Mail-
man, 2007; Urban et al., 2007a) of the pathway that the
interaction ligand-GPCR preferentially activates (Kilts et al.,
2002; Urban et al., 2007b). As an example, both alprenolol
and carvedilol represent b arrestin-biased ligands of the b 1-
adrenergic receptor (Kim et al., 2008) and so are Carvedilol,
ICI118551, propranolol, cyclopenylbutanephrine and norepi-
nephrine for b2 adrenergic receptor (Wisler et al., 2007; Drake
et al., 2008; Azzi et al., 2003). On the other hand, b-arrestin-re-
lated pharmacovigilance is strongly highlighted. Indeed, sev-
eral pharmacological phenomena including tachyphylaxis
and tolerance have been suggested by Erin et al. (Whalen
et al., 2011) to be the results of b-arrestin-dependent receptor
desensitization and downregulation. The same authors have
pointed out the possibility of avoiding such undesirable conse-
quences using biased ligands, thus improving the pharmaco-
logical properties. As illustrations, studies have shown that
cardiac b 1-ARs can stimulate b arrestin1- and -2-dependant
signaling in the heart resulting in transactivation of the epider-
mal growth factor receptor (EGFR), which is cardioprotective
(Noma et al., 2007) whereas, cardiac b-AR desensitization has
been proposed to implicate b-arrestin1 (Conner et al., 1997).
Therefore, the discovery of b-arrestin biased ligands for
b-ARs (Drake et al., 2008; Kim et al., 2008; Wisler et al.,
2007) might provide better therapies in cardiology especially
that chronic treatment with b agonist-stimulated bronchodila-
tor may result in tachyphylaxis (Haney and Hancox, 2006)
,moreover, several publications (Lohse et al., 1990; Ahn
et al., 2003; Deshpande et al., 2008; Perry et al., 2002; Wang
et al., 2009) suggested that G protein-biased ligand could resultate speciﬁcally either G protein (A) or b-arrestin (B) functions via
lications it might have. (The biased ligands binding will stimulate
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therapy as results of the chronic treatment. Other examples
illustrate the role biased ligand can play. Indeed, opioid anal-
gesia and tolerance related to l opioid receptor (OR) have also
been linked to b-arrestins (Bohn et al., 1999, 2000, 2004), thus,
the inﬂuence of b-arrestins on opioid analgesia and tolerance
has been the topic of several studies (Bohn et al., 1999, 2000,
2004; Jiang et al., 2006). On the other hand, other properties
of b-arrestin signaling might provide starting points to develop
new therapies. For cerebral ischemia perspectives, we point
that in vascular smooth muscle cells, activating b-arrestin sig-
naling, in addition to the antiapoptotic effect it has (Ahn et al.,
2009), enhances protein synthesis (DeWire et al., 2008) via the
angiotensin II type 1A receptor (AT1R) mediated pathway.
Following this line, because M3-receptor-dependent learning
and memory functions have been linked to b-arrestin recruit-
ment (Poulin et al., 2010) M3 muscarinic receptor may be a po-
tential target of biased ligands in some pathologies in which
cognitive disorders are affected. In neurological disorders,
whereas aripiprazole, which is an FDA approved atypical anti-
psychotic agent, is considered as a functional selective D2
receptor (D2R or D2) ligands (Lawler et al., 1999; Mailman
and Murthy, 2010; Urban et al., 2007b), UNC9975,
UNC0006, and UNC9994 ,which are analogs of aripiprazole,
were recently shown to be unprecedented b-arrestin-biased
D2R ligands (Allen et al., 2011) which will have a positive im-
pact on both antipsychotic efﬁcacy and side effects reduction
(Allen et al., 2011).
This new concept comes to add new elucidated properties
about GPCRs that could be beneﬁcial both to improve thera-
peutic efﬁciency and reduce side effects. Continued efforts in
this area will lead to the development of new generations of
ligands which have the ability to stimulate speciﬁcally either
b-arrestin or G protein functions via the selectivity they have
at the receptor level, thus controlling the intracellular path-
ways. We might also predict drugs that directly target either
b-arrestin or G protein and thus stimulate or inhibit the related
mechanisms which will result in providing a synergic effects or
reducing undesirable side effects. On the other hand, such new
data will surely help to better understand the diverse cellular
and molecular mechanisms involved in GPCRs’ functions. In
spite of this, many efforts remain to be provided because
existent functionally selective GPCRs’ ligand number still is
limited (Kilts et al., 2002; Mailman, 2007; Urban et al.,
2007a,b; Violin and Lefkowitz, 2007) which constitute a strug-
gle facing the development of this ﬁeld.
4.2. G protein subunits
Among the two G protein subunits, Ga subunit and Gbc sub-
unit (Gilman, 1987; Seneviratne et al., 2011), Gbc subunit, due
to the mechanisms it mediates, is emerging as a pharmacolog-
ical target. As for instance, Gbc-dependent pathway has been
involved in l-opioid potency (Xie et al., 1999), drug addiction
(Yao et al., 2003) and cancer metastasis (Bookout et al., 2003).
In fact, Gbc subunits mediate different functions via a huge
amount of intracellular effectors and interactions including
adenylate cyclase (AC); G protein coupled receptor kinase 2
(GRK2) (Pitcher et al., 1992);phospholipase Cb1, b2 and b3
isoforms (Camps et al., 1992; Park et al., 1993; Smrcka and
Sternweis, 1993); potassium channels (GIRK), phosphoinosi-tide 3 kinase c (PI3Kc) (Stephens et al., 1994; Stephens
et al., 1997); phosphatidylinositol-3-kinase beta (PI3Kb)
(Guillermet-Guibert et al., 2008) and N-type calcium channels
(Ikeda and Dunlap, 1999). Therefore, modifying Gbc Sub-
units’ activity might be of a therapeutical potential. Indeed,
it has been suggested that blocking Gbc signaling can stop
the development of heart failures (Koch et al., 1995; Rockman
et al., 1998) and blocking Gbc-dependent regulation of PI3Kc
may inhibit neutrophil dependent inﬂammation. Moreover,
targeting Gbc might constitute therapeutical approaches
(Casey et al., 2010; Mathews et al., 2008) for opioid-dependent
antinociception (Bonacci et al., 2006; Mathews et al., 2008);
inﬂammation (Lehmann et al., 2008) and cardiac hypertro-
phy(Casey et al., 2010) thus, new chemical entities that, mainly
inhibit Gbc activity, unveil novel opportunities for pharmaco-
therapies (Casey et al., 2010; Mathews et al., 2008). Impor-
tantly, a screening of small molecule identiﬁed compounds
that may bind to Gbc (Seneviratne et al., 2011), thus, stop
Gbc subunit-related signal transduction. The small molecules
identiﬁed in this screening modify the signal transduction be-
tween Gbc and the related effectors, conﬁrming evidence
brought out by several previous publications (Irannejad and
Wedegaertner, 2010; Kirui et al., 2010; Zhao et al., 2007).
Pharmacodynamically, we notice that the interaction between
those small molecules and Gbc subunits was reversible, spe-
ciﬁc, stoichiometric selective in both in vitro and in cells trials
(Seneviratne et al., 2011). Those potential pharmakons have
the advantages to effect even after the receptor has been acti-
vated, showing key properties about therapeutic strategy,
which differentiate GPCRs from ionotropic receptors.
4.3. G protein coupled receptor kinases (GRKs)
GPCRs are mainly regulated by G protein coupled receptor ki-
nases (GRKs) that are involved is homologous desensitization
of GPCRs (Gurevich et al., 2012). Numerous signaling path-
way abnormalities involve GRK dysfunctions (Gurevich
et al., 2012) which highlight the potentials targeting GRKs
may have in therapeutics. Indeed, changes in GRK expression
and function appear to be critical in the regulatory aspects of
vasoconstriction and vasorelaxation homeostasis with advanc-
ing age (Schutzer et al., 2011) and certain neurological and
psychiatric disorders can be treated by therapies that inﬂuence
GRKs activity (Ahmed et al., 2010) such as gene therapy that
elevates the GRK function (Gurevich et al., 2012) via enhanc-
ing GRK expressions .
Observations have shown a link between Alzheimer’s dis-
ease (AD) and some GRKs. In AD patients, GRK2 was
upregulated in endothelial cells (Obrenovich et al., 2006), in
addition, high expression of GRK2 protein and mRNA was
reported as well (Leosco et al., 2007). Furthermore, whereas,
GRK5 activity decrease causes b amyloid accumulation
(Cheng et al., 2010) with the known consequences that are re-
lated to the role that b-amyloid plays in the pathophysiology
of AD, neuroﬁbrillary tangles that are observed in AD patients
have been shown to be linked with GRK2 (Takahashi et al.,
2006) . On the other hand, L-DOPA-induced dyskinesia
(LID) is a side effect observed after a long term treatment with
L-DOPA, which is used in Parkinson’s disease (PD) (Fahn,
2008), moreover, the chronic treatment with L-DOPA has
been linked to GRK2 and GRK6 level reduction in the striatal
120 A. Ghanemiregions(Bezard et al., 2005). Recently a study (Ahmed et al.,
2010) has pointed that an increased level of GRK6 can sup-
press (LID) and has suggested that dyskenesia involves
GRK6-mediated regulation of the dopamine receptor path-
way. Within the brain also, numerous papers have linked
GRKs with both depression phenomena (Garcia-Sevilla
et al., 1999; Grange-Midroit et al., 2003; Taneja et al., 2011;
Vollmayr and Henn, 2001) and antidepressant drugs action
(Gurevich et al., 2012). In fact, whereas, increased level of
GRK3 in select brain regions can play a role in depression
(Barrett et al., 2003, 2007; Zhou et al., 2008), depressive pa-
tients have a high expression of GRK2/3 in their brains
(Garcia-Sevilla et al., 1999; Grange-Midroit et al., 2003).
Because inﬂammatory mediators, that constitute key mole-
cules in immune system signaling, modulate GRKs signaling
(Fan and Malik, 2003; Lombardi et al., 2007), transcription
(Fan and Malik, 2003; Ramos-Ruiz et al., 2000) or degrada-
tion (Cobelens et al., 2007; Lombardi et al., 2002), we might
target GRKs to modify the effects produced by inﬂammatory
mediators but we still need to clarify which mediator is related
to which GRK(s). Furthermore, multiple sclerosis (Poulin
et al., 2010) or secondary progressive MS involves inﬂamma-
tory phenomena that have been linked to GRK and patients
with active relapsing-remitting MS or with secondary progres-
sive MS have a reduced GRK2 contents in the peripheral
blood mononuclear cells(Giorelli et al., 2004; Vroon et al.,
2005). On the other hand, pain, which is in many phenomena
associated with inﬂammation, has GRK2 as a mediator in its
pathway. Thus, we can suppose a possible targeting of GRK
to deal with pain. Indeed, in allodynia, GRK2 expression
was shown to be modiﬁed (Eijkelkamp et al., 2010; Kleibeuker
et al., 2007). Furthermore, it has been shown that induced
chronic paw inﬂammation decreases GRK2 in the dorsal root
ganglia (Eijkelkamp et al., 2010) and in microglia/macro-
phages (Willemen et al., 2010). Following the same way
whereas, chronic hyperalgesia involves selective knockdown
of GRK2 in microglia/macrophages (Eijkelkamp et al., 2010;
Willemen et al., 2010), inﬂammatory mediator (including cyto-
kines, chemokines, peptides, and neurotransmitters) effects re-
sult in hyperalgesia and allodynia (Linley et al., 2010).
GRKs have also been linked to several cardiovascular dis-
eases involving in their pathophysiology autonomous nervous
system’s receptors like catecholamines which activate bARs
that regulate heart function (Gurevich et al., 2012). As illustra-
tion of the therapeutical perspectives, treatment of mice with
cardiac-speciﬁc ablation of GRK2 resulted in cardiomyopathy
(Matkovich et al., 2006). Moreover, cardiac hypertrophy and
early heart failure have been pointed as promoted by the accu-
mulation of GRK5 in the nuclei of cardiac myocytes (Martini
et al., 2008). Importantly, GRKs 2 and 5 are considered as tar-
gets in some cardiac diseases (Penela et al., 2006). Indeed, in
addition to polyanionic compounds heparin and dextran sul-
fate are examples of inhibitors of GRK2(Benovic et al.,
1989), selective potent inhibitors for GRK2/3 subfamily have
been developed by Takeda Pharmaceuticals (Gurevich et al.,
2012; Thal et al., 2011) which adds novel pharmakons to the
cardiovascular diseases’ arsenal.
Although insufﬁcient or excessive GRK activity is involved
in a variety of pathologies, the pharmacological value of
GRKs as potential targets remains under-appreciated
(Gurevich et al., 2012). Compared with ion channel linked
receptors the existence of GRKs constitutes an advantage ofGPCRs as it allows a control of the effects regardless of the li-
gand–receptor binding status. Moreover, as GRKs are not
only involved in GPCR control and can also react according
to a phosphorylation-independent pathway (Gurevich et al.,
2012), targeting them may constitute therapies for a higher
number of disease or cellular dysfunctions. In addition, among
about 500 protein kinases coded by the human genome
(Manning et al., 2002), many have been linked to cardiovascu-
lar diseases (CVDs) such as Rho Kinase (see the next subtitle:
4.4.), Protein kinase C, Glycogen synthase kinase-3b,G-pro-
tein-coupled receptor kinases, Phosphoinositide 3-kinase,
Mitogen-activated protein kinase, and Ca2+/calmodulin
dependent protein kinase II (Kumar et al., 2007). Further-
more, protein kinase signaling pathways have been described
in both acute and chronic CVDs (Dorn and Force, 2005;
Touyz and Schiffrin, 2000).Thus, targeting the related kinase
implicated in the pathophysiological pathway rather than tar-
geting the GPCRs provides important pharmacological op-
tions for CVDs. For example, cardiac b-adrenergic systems
involve protein kinases, using protein kinase inhibitors could
be more advantageous than receptor antagonists (Kumar
et al., 2007). Protein kinase inhibitor does not inhibit the recep-
tor stimulation but it blocks signal transduction.4.4. G protein signaling (RGS) and Rho/Rho kinase
Another aspect of the b-adrenergic receptor (bAR) of the sym-
pathetic nervous system draws attention to novel concepts
about targeting GPCRs’ pathway system. Regulator of G pro-
tein signaling (RGS) proteins are very interesting molecules in
both understanding pathways and therapeutics related to
GPCRs’ system. RGS proteins include GTPase-activating pro-
teins (GAPs) and thus, terminate indirectly G protein signaling
after the GPCR activation (Hollinger and Hepler, 2002; Ross
and Wilkie, 2000). On the other hand, bAR, a GPCR that in-
volves RGS in its pathway, is implicated in cardiac function
(Rockman et al., 2002). Furthermore, pathogenesis of cardiac
hypertrophy and hypertension involves dysfunctions of RGS2
(Wieland et al., 2007). In addition, to RGS 2, the mammalian
cardiac myocytes include also RGS3–5 (Riddle et al., 2005).
Importantly, a recent research (Chakir et al., 2011) has demon-
strated that RGS2 constitutes a novel negative regulator of the
b2AR-Gi signaling in human species. The same study pointed
that the therapeutic implications of the ﬁnding are promising
and a potential novel target has come out to treat chronic
heart failure (Chakir et al., 2011). Such ﬁndings may bring
new ideas about targeting GPCRs’ system for a pharmacolog-
ical purpose.
Within a similar thinking way, another therapeutic possibil-
ity has been highlighted. Small guanosine triphosphatase
(GTPase) Rho and its target Rho kinase (Rho/Rho kinase)-re-
lated signal transduction pathway constitute a key element in
vasoconstriction (Johns et al., 2000). Thus, agents that inhibit
this signaling pathway may have beneﬁts within the cerebral
vascular system via two mechanisms, the ﬁrst is (1): Preventing
cerebrovascular accidents, indeed, as it has been shown that
Rho and Rho kinase may have an important role in regulating
arterial blood pressure thus, targeting this signaling pathway
may provide an important antihypertensive treatment (Uehata
et al., 1997). We note that statistics has indicated that treating
hypertension result in a 48% reduction in the incidence of cere-
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second mechanism is (2): The inhibition of Rho and its tar-
get-related pathway may provide positive results in cerebral
spasm treatment (Jalil et al., 2005) and thus, makes this area
more promising, especially that Rho kinase was linked to sev-
eral endocellular functions including cytokinesis, gene expres-
sion, the organization of the actin cytoskeleton (Uehata
et al., 1997) and reactive oxygen species (ROS) production
(Noma et al., 2006).
Some GPCRs’ ligands, including angiotensin II and phenyl-
ephrine, activate GTPase Rho which activates Rho kinase
then, the activated Rho kinase phosphorylates myosin light
chain phosphatase (Jalil et al., 2005), this leads to myosin light
chain phosphatase inhibition (Jalil et al., 2005).Thus, the idea
of targeting the enzymes involved in this pathway may lead to
the development of novel agents, mainly inhibitors, which will
provide new therapies for some cerebral angiopathies such as
cerebral ischemia and other cardiovascular diseases that have
incidences on certain cerebral and neurological diseases, espe-
cially if targeting such molecules will also modulate the other
functions that have been linked to Rho/Rho kinase such as
some cholesterol-independent cardioprotective effects of statin
therapy (Noma et al., 2006) which may expand more the ther-
apeutic use. For example, fasudil, a Rho-dependent kinase
inhibitor illustrates well the cerebral implications of targeting
this pathway. In fact, Fasudil size in mice, for which the cere-
bral artery was occluded, has two actions (1) increased cerebral
blood ﬂow and (2) reduced infarct size (Kumar et al., 2007)
showing how elucidating, then exploiting the physiological
function of Rho/Rho kinase, and by extrapolation RGS, can
lead to novel pharmacological applications.4.5. Cyclic adenosine monophosphate (cAMP) and lipoic acid
(LA)
Several GPCRs have been related to cAMP-dependent signal-
ing pathway. Because cAMP has different important roles, the
related pathways remain a promising pharmacological target.
Indeed, cAMP is involved in proliferation, migration, apopto-
sis and gene expression processes (Brosens and Gellersen,
2006; Chen et al., 2000; Schillace and Carr, 2006). In addition,
whereas, cAMP plays an important regulatory role during the
inﬂammatory process (Schillace and Carr, 2006), numerous
papers have pointed that cAMP elevating agents were able
to inhibit lymphocyte proliferation, activation and function,
cAMP elevating agents can also decrease histamine, leukotri-
enes, reactive oxygen species, cytokines, chemokines secretion,
monocyte and neutrophil mobility as well (Joshi et al., 2001;
Kuklina and Shirshev, 2000; Moore and Willoughby, 1995;
Roder et al., 1980; Salinthone et al., 2008).
On the other hand, previous studies have shown that lipoic
acid (LA), induces cAMP synthesis (Salinthone et al., 2008;
Schillace et al., 2007) showing a common pathway for
both cAMP and LA. The LA is an endogenous molecule
(Morikawa et al., 2001) with antioxidant properties (Maitra
et al., 1995; Nickander et al., 1996; Whiteman et al., 1996)
allowing it to have therapeutic usages in Alzheimer’s disease,
diabetic polyneuropathy and atherosclerosis (Salinthone
et al., 2011). In addition, the LA was also pointed as neuropro-
tective against brain ischemic damage (Wolz and Krieglstein,
1996). Furthermore, the LA has been shown to be involvedin immune process with anti-inﬂammatory properties. The
LA decreases immune cells migration ability by inhibiting
the expression of adhesion molecules (Chaudhary et al.,
2006; Kunt et al., 1999).It inhibits also both cell activation
and cytolytic function of Natural killer cells (NK cell) (Salinth-
one et al., 2008). Within some immune cells, cAMP synthesis,
considered herein as an immunomodulator, is mediated by the
LA (Salinthone et al., 2008; Schillace et al., 2007).
Two kinds of enzymes, phosphodiesterases (PDEs) and
adenylyl cyclases (including transmembrane ACs (tmACs)
and soluble ACs (sACs)) (Xiao et al., 2007, 2010) regulate
cAMP cellular content (Buck et al., 1999; Neves et al., 2002).
On the other hand, many GPCRs including prostanoid EP2
and EP4 receptors, histamine, adenosine and b adrenergic
receptors have been shown to regulate tmACs (Neves et al.,
2002). Moreover, data from many papers, together, lead us
to suppose a relationship between LA activation of mecha-
nisms, other than those linked with EP receptor’s, and the syn-
ergistic effects on cAMP production of LA and PGE2 (Han
et al., 2005; Schmid et al., 2007; Sinclair et al., 2000; Stessin
et al., 2006; Young et al., 2008; Zippin et al., 2003, 2004).
Importantly, a recently published study (Salinthone et al.,
2011), highlighted more new evidence and has conﬁrmed that,
histamine receptors and adenosine receptors are also media-
tors of LA stimulated cAMP production, in addition, LA stim-
ulates soluble ACs and, more importantly, LA induces cAMP
synthesis. The same paper has also pointed that LA does not
activate b-adrenergic receptors (Salinthone et al., 2011). More-
over, tmACs activation can result from LA prostanoid and
EP2/EP4 receptors’ binding (Salinthone et al., 2008; Schillace
et al., 2007). These new ﬁndings are consistent with the data
we have about the role histamine receptors and adenosine
receptors play during inﬂammation. Whereas, histamine H2
receptors on peripheral monocytes stops interleukin (IL)-12
production (Elenkov et al., 1998), adenosine inhibits cytokine
production in NK cells (Lokshin et al., 2006; Raskovalova
et al., 2006) .
Several researches are highlighting the effects of LA treat-
ment, indeed the LA reduces or inhibits several immune pro-
cesses that are involved in the inﬂammatory phenomena
(Chaudhary et al., 2006; Kunt et al., 1999; Marracci et al.,
2006; Salinthone et al., 2008). Following this line of thought,
anti-inﬂammatory effects of LA may involve adenosine recep-
tors (Salinthone et al., 2011).Therefore, for Alzheimer’s disease
(AD) and some other disease, due to their inﬂammatory com-
ponent, cAMP has been targeted by therapies (McPhee et al.,
2005; Osadchii, 2007).These novel elements about the de-
scribed anti-inﬂammatory and the anti-oxidant properties of
cAMP, cAMP pathway-related molecules and different recep-
tors, mainly histamine and adenosine receptors, make them
potential targets in several diseases that have inﬂammatory
component or pathologies that may be improved with anti-oxi-
dant agents as protective molecules such as multiple sclerosis,
diabetic polyneuropathy, brain ischemia damages, in addition
to neurodegenerative diseases including Alzheimer’s disease,
Parkinson’s disease, and sclerosis.
The fact that LP and cAMP pathways are not together in all
the pathways makes the chances of discovering new drugs with
fewer side effects higher as we may target cAMP pathway inde-
pendently from the LP or we may target the LP independently
from the cAMP (or its pathway) thus, decreasing the impact
on the other bio-functions of the cells via drugs’ selectivity.
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In addition to the previous illustrative examples which indicate
how modifying the GPCR-related pathways can provide novel
therapies, we suppose that the compounds that have the ability
to interact with the cytoplasmic GPCR-related mechanisms
may be very helpful for the study and the characterization of
different pathways when a new drug is being investigated dur-
ing laboratory researches. For example, the persistence of drug
effects while a certain pathway is inhibited can indicate that
that drug does not involve that inhibited pathway. It can also
allow us to illustrate the molecular and the cellular mecha-
nisms that govern some toxicological and pathophysiological
phenomena. Indeed, some toxic compounds and even thera-
peutic agents are organophosphorus (OP) (RamaRao and
Bhattacharya, 2012). OP represents irreversible inhibitors of
the enzyme acetylcholinesterase (AchE) causing acetylcholine
(Ach) accumulation in both peripheral and central nervous
systems, which mainly explains the acute OP toxicity (Duysen
et al., 2001) during which we observe hypersecretions, respira-
tory distress, tremor, seizures/convulsions, coma and induced
chronic neurotoxicity (Damodaran et al., 2006; Miyaki et al.,
2005). In addition to cholinergic-related signs, other nerve
agent poisoning effects have been linked to glutamate and
GABAergic receptors with diacylglycerol and calcium as sec-
ond messengers (RamaRao and Bhattacharya, 2012). More-
over, this toxicity activates neuronal structure protein
(Chebabo et al., 1999; Ward et al., 1993) and has been also re-
lated to mutagenic, stressogenic, immunologic, hepatotoxic,
membrane and hematotoxic effects (Kassa et al., 2001).
GPCRs and receptors with intrinsic tyrosine kinase activity
have been shown to play a role in those processes (Costa,
1998). Furthermore; several other toxic effects have also been
pointed. In fact, it modiﬁes gene expression of key-cholinergic
proteins (Bansal et al., 2009; Kaufer et al., 1998; Meshorer and
Soreq, 2006), in addition, it has exitotoxic damage in the piri-
form cortex, entorhinal cortex, amygdala, and hippocampus
(Lallement et al., 1991; McDonough and Shih, 1997) (Lalle-
ment et al., 1992; Solberg and Belkin, 1997). Whereas, a recent
study has shown that after nerve agent exposure of the rat
brain, cerebral cortex and cerebellum regions have high l-cal-
pain contents (RamaRao et al., 2011), in both Alzheimer’s and
Parkinson’s diseases, increased calpain was shown to play a
role (Camins et al., 2006; Saito et al., 1993) which is likely to
contribute to our understanding of these neurodegenerative
diseases. On the other hand, during nerve agent exposure,
alterations of diverse neural processes including purinergic,
NMDA-glutamatergic, GABAergic, catecholaminergic, sero-
togenic and calcium pathways in addition to neurodegenera-
tion, dementia process, learning and memory alterations, are
reported phenomena (Damodaran et al., 2006; Dillman
et al., 2009; Pachiappan et al., 2009). Such novel description
of the nerve agent toxicity will provide, if combined with fur-
ther researches in pharmacology and molecular biology, new
data to both understand the pathophysiology and ﬁnd out
therapeutics that may target the molecular elements implicated
in the nerve agent toxicity pathway (GPCR and its second
messengers, DNA and enzymes). On the other hand, the nerve
agent has been linked to Alzheimer’s and Parkinson’s diseases
(RamaRao and Bhattacharya, 2012). Therefore, such data al-
low us to learn more about the etiology of both neurodegener-ative diseases and even to develop therapies through clarifying
their molecular mechanisms and considering the implicated
molecules (mainly enzymes and DNA) as novel targets to im-
prove pathologies prognostics or slow down of the disease evo-
lution. Investigations on laboratory regents or solvents, that
are supposed to be bio-neuter but for which biological or phar-
macological properties have been reported can also constitute
starting points to drug development (Ghanemi, 2013a). Impor-
tantly, such novel drugs could treat the pathologies or the dis-
orders in which acetylcholine signaling has been shown to play
roles, in both the CNS and peripheral nervous system.
6. Conclusion
Although we pointed selected examples about targeting
GPCRs’ pathways, the existent structural and functional sim-
ilarities between the different GPCRs suppose that, a property
shown for a GPCR in certain diseases or disorders may be, by
extrapolation, applicable for other GPCRs within related
pathophysiological cases.
The description of molecular mechanisms of diseases that
will improve our understanding of pathophysiological phe-
nomena, together with the data provided within this review
about – mainly but not only – molecular aspects of GPCR-re-
lated pathways will have important implications in both in vivo
and in vitro researches. Furthermore, the possibilities of
designing new research protocols and eventually providing
data to other research areas including molecular biology and
physiology based on the above concepts constitute interesting
topics.
Importantly, the advances provide elements and concepts
that may lead to further drug development by giving starting
points for new molecular therapeutics’ ﬁelds especially if it
considers the other factors that have been shown to inﬂuence
the pharmacodynamics of diverse GPCRs (Ghanemi et al.,
2013) and the increased discoveries about different enzymes
and molecules that control the downstream of the GPCR path-
ways with the description of the cellular, enzymatic and molec-
ular interactions that govern the related pathways.
In contrast, within different systems, such as the central
nervous system, the GPCRs interact with each other and with
other receptors to form complex networks, such as in some
psychiatric diseases (Ghanemi, 2013b). Thus, a drug that inter-
acts with an element from the GPCR system might inﬂuence
such networks and result in complexes’ side effects. Therefore,
such approach must apply a severe pharmacovigilance, espe-
cially if the corresponding pathways control important
in vivo functions of drugs that target GRCR related pathways.
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